Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Müller

Showing results (491-500 of 651) with videos related to

Pageof 66
Sort By:
Blood|November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsGuido Bisping, Martin Kropff, Doris Wenning, et al.
Leukemia|October 11, 2023
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disordersSebastian Köhrer, Tobias Dittrich, Martin Schorb, et al.
NPJ Digital Medicine|March 21, 2024
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceJan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
Acta Haematologica|April 12, 2017
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center AnalysisGabriela B Thoennissen, Dennis Görlich, Ulrike Bacher, et al.
Frontiers in Oncology|April 7, 2022
Point Mutations in the <i>FLT3</i>-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant <i>KMT2A</i>-PTDSebastian Stasik, Michael Kramer, Sven Zukunft, et al.
Blood Advances|September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLJulia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Leukemia Research|December 24, 2010
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survivalLara Tickenbrock, Hans-Ulrich Klein, Cristina Trento, et al.
Cancer Cell|March 10, 2023
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsMirco J Friedrich, Paola Neri, Niklas Kehl, et al.
Hemasphere|April 23, 2025
Phosphatidic acid phosphatase LPIN1 in phospholipid metabolism and stemness in hematopoiesis and AMLKarin Huber, Swati Garg, Lena Schlautmann, et al.
Pageof 66

Showing results (491-500 of 651) with videos related to

Sort By:
Pageof 66
Blood|November 10, 2005
Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsGuido Bisping, Martin Kropff, Doris Wenning, et al.
Leukemia|October 11, 2023
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disordersSebastian Köhrer, Tobias Dittrich, Martin Schorb, et al.
NPJ Digital Medicine|March 21, 2024
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceJan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, et al.
Acta Haematologica|April 12, 2017
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center AnalysisGabriela B Thoennissen, Dennis Görlich, Ulrike Bacher, et al.
Frontiers in Oncology|April 7, 2022
Point Mutations in the <i>FLT3</i>-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant <i>KMT2A</i>-PTDSebastian Stasik, Michael Kramer, Sven Zukunft, et al.
Blood Advances|September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLJulia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Leukemia Research|December 24, 2010
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survivalLara Tickenbrock, Hans-Ulrich Klein, Cristina Trento, et al.
Cancer Cell|March 10, 2023
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsMirco J Friedrich, Paola Neri, Niklas Kehl, et al.
Hemasphere|April 23, 2025
Phosphatidic acid phosphatase LPIN1 in phospholipid metabolism and stemness in hematopoiesis and AMLKarin Huber, Swati Garg, Lena Schlautmann, et al.
Pageof 66